News | Ventricular Assist Devices (VAD) | April 03, 2017

New Protocol at Henry Ford Hospital Dramatically Increases Heart Attack Survival Rates

Analysis of more than 15,000 heart attack patients finds hospitals achieved survival rates up to 75 percent with implantation of Impella pump before any other intervention

Henry Ford Hospital, Detroit Cardiogenic Shock Initiative, Impella pump, ACC.17 clinical study

April 3, 2017 — Hospitals can dramatically increase heart attack survival rates in patients suffering cardiogenic shock by providing rapid hemodynamic support before treating the cause of a heart attack, according to a new analysis that included more than 15,000 patients across the United States.

Doctors in Detroit increased survival rates from 50 percent to 84 percent by following a protocol developed using a straw-sized heart pump, said cardiologist William W. O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital.

“This shows that if you can apply these best practices systematically, you can dramatically increase survival in cardiogenic shock,” said O’Neill, who presented the analysis at the American College of Cardiology’s Scientific Sessions, March 17-19 in Washington, D.C., offering to train other centers in the life-saving approach. “We believe the protocol can benefit patients nationwide.”

Watch a VIDEO interview with O'Neill at ACC.17  - "Cardiogenic Shock Supported With Impella Shows Good Outcomes."

Cardiogenic shock is a complication of heart attacks that affects approximately 5-8 percent of patients in the United States annually. In these patients, the pump function of the heart is severely depressed, causing low blood pressure and vital organs to be deprived of sufficient blood supply. Despite contemporary treatments, an average of about 50 percent of patients experiencing the condition die.

The analysis looked at the use of the Impella, a straw-sized pump approved by the U.S. Food and Drug Administration (FDA) in 2008 and specifically for treatment of cardiogenic shock in 2016. The pump is inserted through a catheter in the groin and into the heart to keep blood pumping throughout the body. Doctors use it while they are treating the cause of a heart attack, either by inserting a stent, removing a clot or taking other necessary action while the tiny pump supports circulation.

Watch the VIDEO "Demonstration of the Impella Percutaneous Hemodynamic Support Device."

The analysis retroactively looked at data collected by Abiomed, the pump’s manufacturer, in 15,529 patients – 72 percent men and an average age of 63 – treated between 2009 and 2017.

The investigators noticed that survival rates in patients treated with the Impella pump fluctuated wildly by hospital, O’Neill said. A third of hospitals experienced a 25 percent survival rate; a third, 50 percent survival; and a third, 75 percent.

“There was a huge variation in outcomes between the centers, between the lowest performing and highest performing centers,” said O’Neill. “It looked as though putting the Impella in soon, before you do anything else, is connected to survival.”

Inserting the pump first ensures the patient’s other vital organs are supported, buying time for cardiologists to open the blocked arteries to restore natural blood flow. The hospitals with high survival rates also used less inotropes and correctly sized catheters to monitor heart pressure, O’Neill added.

To test the best practices, O’Neill organized five hospital systems in southeast Michigan to follow a specific protocol in ST-elevation myocardial infarction (STEMI) patients who showed signs of cardiogenic shock between July 2016 and Jan. 2017. Of the 37 patients supported with the Detroit Cardiogenic Shock Initiative protocol, 31 (84 percent) survived.

“Some of these breakthroughs are so straightforward, you wonder, why didn’t we think of it before?” said O’Neill. “We believe this approach can benefit patients nationwide.”

Participants with Henry Ford Health System in the Detroit Cardiogenic Shock Initiative include Beaumont Hospital, Detroit Medical Center, Ascension’s St. John and Providence hospitals and Saint Joseph Mercy Health System. 

“Cardiologists have been trying to move the needle on heart attack survival rate for years; this is a huge success,” said Thomas Lalonde, M.D., chief of cardiology at St. John Hospital in Detroit.

Key to the protocol is medical personnel recognizing cardiogenic shock in patients as soon as possible, O’Neill added.

“If they think the patient needs medication to raise the blood pressure, that’s when they should be thinking, ‘Get them someplace where they can get a pump implanted,’” said O’Neill, who intends to help other hospital systems across the United States implement the protocols.

Read about another cariogenic shock study presented at ACC.17, “Study Examines Influence of Cardiac Arrest and Cardiogenic Shock on STEMI Patient Outcomes.”
 

The the article “Collaboration by Metro Detroit Cardiologists Increases Cardiogenic Shock Survival Rate.”

For more information: www.henryford.com/cardiogenicshock

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init